表紙
市場調查報告書

臨床服務市場及產業未來預測 (2020∼2030年):早期/晚期階段服務、製藥企業、生物科技企業、癌症、心血管疾病、中樞神經系統疾病 (CNS)、傳染病、代謝性疾病、其他

Pharma Clinical Trial Services Market and Industry Forecast 2020-2030: Early Phase & Late Phase Services, Pharma, Biotech, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other

出版商 Visiongain Ltd 商品編碼 935844
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
臨床服務市場及產業未來預測 (2020∼2030年):早期/晚期階段服務、製藥企業、生物科技企業、癌症、心血管疾病、中樞神經系統疾病 (CNS)、傳染病、代謝性疾病、其他 Pharma Clinical Trial Services Market and Industry Forecast 2020-2030: Early Phase & Late Phase Services, Pharma, Biotech, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other
出版日期: 2020年03月20日內容資訊: 英文 200 Pages
簡介

預估全球臨床服務 (臨床試驗服務) 市場將於預測期間前半期 (2020∼2030年) 以10%的CAGR成長,於2030年來到1501億5000萬美元規模。

本報告研究全球製藥企業的臨床服務市場,彙整市場基本結構與特性、市場規模趨勢展望,提供按服務、末端使用、治療領域、功能的詳細動向,以及區域和主要國家市場結構及趨勢、主要企業簡介等情報。

第1章 分析概要

第2章 臨床服務市場:概要

  • 臨床:歷史展望
  • 臨床設計和實行
  • 臨床階段 (Phase)
    • Phase I試驗:最初人體研究
    • Phase II試驗:概念實證
    • Phase III試驗:核准申請
    • 上市後研究
    • 臨床重要要素
  • 一般臨床設計
    • 透過適應性設計之臨床模型改善
    • 臨床試驗外包
      • 進行臨床試驗時的課題
      • 外包優點

    第3章 全球臨床服務市場:按服務 (2020∼2030年)

    • 景氣對臨床服務市場的影響 (2019∼2030年)
    • 臨床服務市場:按服務 (2019∼2030年)
      • 早期階段服務
      • 晚期階段服務
      • 其他臨床試驗服務市場預測2019-2030

    第4章 全球臨床服務市場:按末端使用 (2020∼2030年)

    • CRO (委託研究機構) 的演進
    • 臨床服務市場:按末端使用 (2020∼2030年)
      • 製藥企業
      • 生物科技企業
      • 其他末端使用

    第5章 全球臨床服務市場:按治療領域 (2020∼2030年)

    • 主要治療領域中臨床服務的抬頭
      • 癌症
      • 心血管疾病
      • 中樞神經系統 (CNS) 疾病
      • 傳染病
      • 代謝性疾病
      • 其他疾病

    第6章 全球臨床服務市場:按區域 (2020∼2030年)

    • 北美市場預測 (2019∼2030年)
      • 按國家:美國等
      • 按服務
      • 按治療領域
      • 按末端使用
    • 歐洲市場預測 (2019∼2030年)
      • 按國家:法國、德國、英國、西班牙、義大利、俄國、中東歐等
    • 亞太地區市場預測 (2019∼2030年)
      • 按國家:中國、印度、日本、韓國等
    • 其他國家 (RoW) 市場預測 (2019∼2030年)
      • 按區域/國家:拉丁美洲、中東及非洲、巴西

    第7章 市場推動及阻礙因素

    • 市場推動及阻礙因素 (2019∼2030年)
    • 推動因素
      • 全球臨床需求增加
      • 生物醫藥品企業加強研發力度,導致臨床服務利用增加
      • CRO:進入新興國市場並建構強健基礎
      • 生物醫藥品企業研發支出增額:推動臨床市場成長
      • 新興國市場 (特別是中國):臨床服務企業成為高人氣目的地
      • 生物醫藥品企業與CRO的合作強化:使市場受益
    • 阻礙因素
      • 監管面阻礙因素:更長的核准期間
      • 醫師與護士參與度低,導致病患招募率低
    • 課題
      • 高成本

    第8章 臨床服務市場主要企業

    • Quintiles IMS Holdings Inc.
      • 業務概要
      • 主要財務指標
      • 企業策略
    • LabCorp (Covance Inc.)
    • Pharmaceutical Product Development (PPD), LLC
    • Parexel International Corporation
    • ICON
    • INC Research
    • inVentiv Health
    • PRA Health Sciences
    • Chiltern International
    • Charles River Laboratories
    • Wuxi AppTec
    • Almac Group
    • Ancillare, LP
    • KLIFO
    • Catalent, Inc
    • Covance Inc

    第9章 臨床服務市場:STEP分析 (2019∼2030年)

    • 臨床服務市場STEP分析
    • 影響臨床的社會因素
      • 進行臨床試驗的倫理考量事項
      • 病患招募:已開發國家市場主要課題
    • 臨床改良的技術開發
      • 電子數據收集
      • 「eClinical」工具
      • 透過使用電子病例 (EHR)加快病患招募
      • 雲端運算:作為多設施共同臨床工具的使用
    • 臨床外包的經濟考察
      • 製藥企業的研發策略調整
      • CRO:對民間企業的吸引力
    • 臨床外包相關政治和法規考量事項
      • 藥物安全性與市售後調查
      • 減少繁雜手續以及其他監管發展

    第10章 結論

    • 臨床服務市場:目前主力部門
      • 主要CRO
      • 主要地域
      • 新興國臨床服務市場
    • 詞彙表
目錄
Product Code: PHA0729

The pharma clinical trials services market is expected to grow at a CAGR of 10% in the first half of the forecast period and be worth $150.15bn by 2030.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 220-page report you will receive 51 tables and 110 figures- all unavailable elsewhere.

The 220-page report provides clear detailed insight into the pharma clinical trial services market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope:

Pharma Clinical Trial Services Market forecasts from 2020-2030

This report breaks down the revenue forecast for pharma clinical trial services market by type of service:

  • Early Phase Services
  • Late Phase Services
  • Other Services

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

This report breaks down the revenue forecast for pharma clinical trial services market by End-Users:

  • Pharma
  • Biotech Companies
  • Other End-Users

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

This report breaks down the revenue forecast for pharma clinical trial services market by Therapeutic Area:

  • Cancer
  • Cardiovascular
  • CNS
  • Infectious Diseases
  • Metabolic Diseases
  • Other Diseases

Each submarket is further divided by region: North America, Europe, Asia-Pacific and RoW

This report provides individual revenue forecasts to 2030 for these regional and national markets:

  • North America: the US and Rest of North America
  • Europe: France, Germany, the UK, Spain, Italy, Russia, Central and Eastern Europe, Rest of Europe
  • Asia-Pacific: China, India, Japan, South Korea, Rest of APAC
  • Rest of the World: Latin America, Middle East and Africa, Brazil

Each regional market is further divided by type of service, end-users and therapeutic area.

Our study discusses factors that drive and restrain the pharma clinical trial services market. This report also provides a STEP analysis.

This report discusses the leading companies in pharma clinical trial services market:

  • Quintiles, Laboratory Corporation of America (LabCorp)
  • Pharmaceutical Product Development (PPD)
  • Parexel International
  • ICON
  • INC Research Holdings
  • inVentiv Health
  • & Other Companies

Visiongain's study is intended for anyone requiring commercial analyses for the pharma clinical trial services market. You find data, trends and predictions.

Buy our report today Pharma Clinical Trial Services Market and Industry Forecast 2020-2030: Early Phase Services, Late Phase Services, Other Services, Pharma, Biotech, Other End-users, Cancer, Cardiovascular Diseases, CNS, Infectious Diseases, Metabolic Diseases, Other Diseases.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Pharma Clinical Trial Services Market Overview
  • 1.2 Why You Should Read This Report
  • 1.3 Key Questions Answered by This Analytical Report
  • 1.4 Structure of the Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Pharma Clinical Trial Services Market Introduction

  • 2.1 Clinical Trials: A Historical Perspective
  • 2.2 Design and Execution of Clinical Trials
  • 2.3 Phases of Clinical Trials
    • 2.3.1 Phase I Trials: First In-Human Studies
    • 2.3.2 Phase II Trials: Proof-of- Concept
    • 2.3.3 Phase III Trials: Drug Approval Applications
    • 2.3.4 Post-Marketing Studies
    • 2.3.5 Key Elements of Clinical Trials
  • 2.4 Common Trial Designs
    • 2.4.1 Improving Clinical Trial Models through Adaptive Trial Designs
  • 2.5 Clinical Trial Outsourcing
    • 2.5.1 Challenges Exist in Conducting Clinical Trials
    • 2.5.2 Benefits of Outsourcing

3. Pharma Clinical Trial Services: World Market by Services 2020-2030

  • 3.1 The Impact of Economy on the Clinical Trial Services Market 2019-2030
  • 3.2 Pharma Clinical Trial Services Market by Services 2019-2030
    • 3.2.1 Early Phase Clinical Trial Services Market Forecasts 2019-2030
    • 3.2.2 Late Phase Clinical Trial Services Market Forecasts 2019-2030
    • 3.2.3 Other Clinical Trial Services Market Forecasts 2019-2030

4. Pharma Clinical Trial Services: World Market by End-Users 2019-2030

  • 4.1 The Evolution of the Clinical Research Organizations (CROs)
  • 4.2 Pharma Clinical Trial Services Market, by End-Users 2019-2030
    • 4.2.1 Clinical Trial Services Market by Pharma End-Users Forecasts 2019-2030
    • 4.2.2 Clinical Trial Services Market by Biotech Companies End-Users Forecasts 2019-2030
    • 4.2.3 Clinical Trial Services Market by Other End-Users Forecasts 2019-2030

5. Pharma Clinical Trial Services: World Market by Therapeutic Areas 2019-2030

  • 5.1 Rise of Clinical Trial Services in Key Therapeutic Areas
    • 5.1.1 Cancer Clinical Trial Services Market Forecasts 2019-2030
    • 5.1.2 Cardiovascular Diseases Clinical Trial Services Market Forecasts 2019-2030
    • 5.1.3 CNS Diseases Clinical Trial Services Market Forecasts 2019-2030
    • 5.1.4 Infectious Diseases Clinical Trial Services Market Forecasts 2019-2030
    • 5.1.5 Metabolic Diseases Clinical Trial Services Market Forecasts 2019-2030
    • 5.1.6 Other Diseases Clinical Trial Services Market Forecasts 2019-2030

6. Regional Pharma Clinical Trial Services Market Forecasts 2019-2030

  • 6.1 North American Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.1.1 U.S. Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.1.2 Rest of North America Pharma Clinical Trial Services Market Forecasts 2019-2030
  • 6.2 North American Pharma Clinical Trial Services Market Forecasts by Service 2019-2030
  • 6.3 North American Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2019-2030
  • 6.4 North American Pharma Clinical Trial Services Market Forecasts by End-Users 2019-2030
  • 6.5 Europe Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.1 France Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.2 Germany Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.3 U.K. Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.4 Spain Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.5 Italy Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.6 Russia Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.7 Central and Eastern Europe Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.5.8 Rest of Europe Pharma Clinical Trial Services Market Forecasts 2019-2030
  • 6.6 European Pharma Clinical Trial Services Market Forecasts by Service 2019-2030
  • 6.7 European Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2019-2030
  • 6.8 European Pharma Clinical Trial Services Market Forecasts by End-Users 2019-2030
  • 6.9 Asia-Pacific Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.9.1 China Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.9.2 India Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.9.3 Japan Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.9.4 South Korea Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.9.5 Rest of Asia-Pacific (APAC) Pharma Clinical Trial Services Market Forecasts 2019-2030
  • 6.10 Asia-Pacific Pharma Clinical Trial Services Market Forecasts by Service 2019-2030
  • 6.11 Asia-Pacific Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2019-2030
  • 6.12 Asia-Pacific Pharma Clinical Trial Services Market Forecasts by End-Users 2019-2030
  • 6.13 Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.13.1 Latin America Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.13.2 Middle East and Africa Pharma Clinical Trial Services Market Forecasts 2019-2030
    • 6.13.3 Brazil Pharma Clinical Trial Services Market Forecasts 2019-2030
  • 6.14 Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts by Service 2019-2030
  • 6.15 Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts by Therapeutic Area 2019-2030
  • 6.16 Rest of the World (RoW) Pharma Clinical Trial Services Market Forecasts by End-Users 2019-2030

7. Drivers & Restraints

  • 7.1 Drivers and Restraints 2019-2030
  • 7.2 Drivers
    • 7.2.1 Rising Demand of Clinical Trials Worldwide
    • 7.2.2 Increased research and development by biopharmaceutical companies leading to better utilization of clinical trial services
    • 7.2.3 Contract research organizations present in the emerging markets to gain major foothold in the forecast period
    • 7.2.4 Growth of biopharma R&D expenditures will lead to increase in the clinical trial market
    • 7.2.5 Emerging markets especially China becoming a much sought-after clinical trial destination
    • 7.2.6 Increased Strategic Alliances among Large BioPharma Companies and CROs benefitting the market
  • 7.3 Restraints
    • 7.3.1 Regulatory Constraints such as longer approval time for clinical trials
    • 7.3.2 Poor Physician and Nurse Engagement Leading to Low Patient Recruitment Rates
  • 7.4 Challenges
    • 7.4.1 High cost

8. Leading Companies in the Pharma Clinical Trial Services Market

  • 8.1 Quintiles IMS Holdings Inc.
    • 8.1.1 Quintiles IMS Holdings Inc. Business Overview
    • 8.1.2 Quintiles IMS Holdings Inc. Financial Overview
    • 8.1.3 Quintiles IMS Holdings Inc. Corporate Strategy
  • 8.2 LabCorp (Covance Inc.)
    • 8.2.1 LabCorp Business Overview
    • 8.2.2 LabCorp Financial Overview
    • 8.2.3 LabCorp (Covance Inc.) Corporate Strategy
  • 8.3 Pharmaceutical Product Development (PPD), LLC
    • 8.3.1 Pharmaceutical Product Development (PPD) Business Overview
    • 8.3.2 Pharmaceutical Product Development (PPD) Financial Overview
    • 8.3.3 Pharmaceutical Product Development (PPD) Corporate Strategy
  • 8.4 Parexel International Corporation
    • 8.4.1 Parexel International Corporation Business Overview
    • 8.4.2 Parexel International Corporation Financial Overview
    • 8.4.3 Parexel International Corporation Corporate Strategy
  • 8.5 ICON
    • 8.5.1 ICON Business Overview
    • 8.5.2 ICON Financial Overview
    • 8.5.3 ICON Corporate Strategy
  • 8.6 INC Research
    • 8.6.1 INC Research Business Overview
    • 8.6.2 INC Research Financial Overview
    • 8.6.3 INC Research Corporate Strategy
  • 8.7 inVentiv Health
    • 8.7.1 inVentiv Health Business Overview
    • 8.7.2 inVentiv Health Financial Overview
    • 8.7.3 inVentiv Health Corporate Strategy
  • 8.8 PRA Health Sciences
    • 8.8.1 PRA Health Sciences Business Overview
    • 8.8.2 PRA Health Sciences Financial Overview
    • 8.8.3 PRA Health Sciences Corporate Strategy
  • 8.9 Chiltern International
    • 8.9.1 Chiltern International Business Overview
    • 8.9.2 Chiltern International Financial Overview
    • 8.9.3 Chiltern International Corporate Strategy
  • 8.10 Charles River Laboratories
    • 8.10.1 Charles River Laboratories Business Overview
    • 8.10.2 Charles River Laboratories Financial Overview
    • 8.10.3 Charles River Laboratories Corporate Strategy
  • 8.11 Wuxi AppTec
    • 8.11.1 Wuxi AppTec Business Overview
    • 8.11.2 Wuxi AppTec Financial Overview
    • 8.11.3 Wuxi AppTec Corporate Strategy
  • 8.12 Almac Group
    • 8.12.1 Wuxi AppTec Business Overview
    • 8.12.2 Wuxi AppTec Corporate Strategy
  • 8.13 Ancillare, LP
    • 8.13.1 Ancillare, LP Business Overview
    • 8.13.2 Ancillare, LP Corporate Strategy
  • 8.14 KLIFO
    • 8.14.1 KLIFO Business Overview
  • 8.15 Catalent, Inc
    • 8.15.1 Catalent, Inc Business Overview
    • 8.15.2 Catalent, Inc Corporate Strategy
  • 8.16 Covance Inc
    • 8.16.1 Covance Inc Business Overview

9. STEP Analysis of the Pharma Clinical Trial Services Market 2019-2030

  • 9.1 STEP Analysis of the Pharma Clinical Trial Services Market
  • 9.2 Social Factors Affecting Clinical Trials
    • 9.2.1 Ethical Considerations in Conducting Clinical Trials
    • 9.2.2 Patient Recruitment: Major Challenge in Developed Markets
  • 9.3 Technological Development for Improved Trials
    • 9.3.1 Electronic Data Capture
    • 9.3.2 eClinical Trial Tools
    • 9.3.3 Use of Electronic Health Records for Faster Patient Recruitment
    • 9.3.4 Cloud Computing used as a Tool for Multicentre Trials
  • 9.4 Economic Considerations for Clinical Trial Outsourcing
    • 9.4.1 Pharma is adjusting its R&D strategies
    • 9.4.2 CROs tend to be attractive for Private Investigators
  • 9.5 Political and Regulatory Considerations for Clinical Trial Outsourcing
    • 9.5.1 Drug Safety and Clinical Trials Post-Approval
    • 9.5.2 Cutting Red Tape and Other Regulatory Developments

10. Conclusions

  • 10.1 Current Leading Pharma Clinical Trial Services Market Segments
    • 10.1.1 Leading Contract Research Organizations
    • 10.1.2 Leading Regional Markets
    • 10.1.3 Emerging Pharma Clinical Trial Services Markets
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
    • About Visiongain
  • Appendix B
    • Visiongain report evaluation form

List of Tables

  • Table 2.1 Founding Members of the ICH
  • Table 2.2 Types of Adaptive Trial Design
  • Table 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
  • Table 3.2 Breakdown of Pharma Clinical Trial Services by Phase
  • Table 3.3 Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 3.4 Early Phase Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 3.5 Late Phase Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%) 2019-2030
  • Table 3.6 Other Pharma Clinical Trial Services Markets by Region: Forecast ($bn, AGR%, CAGR%) 2019-2030
  • Table 4.1 Pharma Clinical Trial Services Submarket by End-Users: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 4.2 Clinical Trial Services Pharma Submarket by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 4.3 Clinical Trial Services Biotech Companies Submarket by Region: Forecast ($bn, AGR%, CAGR%) 2019-2030
  • Table 4.4 Clinical Trial Services Other End-Users Submarket by Region: Forecasts ($bn, AGR%, CAGR%), 2019-2030
  • Table 5.1 Pharma Clinical Trial Services Submarkets by Therapeutic Area: Forecast ($bn, AGR %, CAGR%), 2019-2030
  • Table 5.2 Cancer Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 5.3 Cardiovascular Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 5.4 CNS Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 5.5 Infectious Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 5.6 Metabolic Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 5.7 Other Diseases Clinical Trial Services Market by Region: Forecast ($bn, AGR%, CAGR%), 2019-2030
  • Table 6.1 Regional Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.2 U.S. Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%, 2019-2030
  • Table 6.3 Rest of North America Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.4 North American Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.5 North American Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.6 North American Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.7 France Pharma Clinical Trial Services Market: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.8 Germany Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.9 U.K. Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.10 Spain Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.11 Italy Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.12 Russia Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.13 Central and Eastern Europe (CEE) Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.14 Rest of Europe Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.15 European Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.16 European Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.17 European Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.18 China Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.19 India Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.20 Japan Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.21 South Korea Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.22 Rest of Asia-Pacific (APAC) Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.23 Asia-Pacific Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.24 Asia-Pacific Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.25 Asia-Pacific Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.26 Latin America Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.27 Middle East and Africa Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.28 Brazil Pharma Clinical Trial Services Market: Forecasts ($bn, AGR% CAGR%), 2019-2030
  • Table 6.29 RoW Pharma Clinical Trial Services Market by Service: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.30 RoW Pharma Clinical Trial Services Market by Therapeutic Area: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 6.31 RoW Pharma Clinical Trial Services Market by End-Users: Forecast ($bn, AGR% CAGR%), 2019-2030
  • Table 9.1 STEP Analysis of Pharma Clinical Trial Services Market 2019-2030

List of Figures

  • Figure 2.1 Brief History of Clinical Trials
  • Figure 3.1 Breakdown of Pharma Clinical Spending by Phase
  • Figure 3.2 Global Pharma Clinical Trial Services Market by Service: (% Share), 2020
  • Figure 3.3 Global Pharma Clinical Trial Services Market by Service: (% Share), 2025
  • Figure 3.4 Global Pharma Clinical Trial Services Market by Service: (% Share), 2030
  • Figure 3.5 Pharma Clinical Trial Services Market by Services: Revenue ($bn), 2019-2030
  • Figure 3.6 Early Phase Services Market Forecasts: Revenue, $Bn 2019-2030
  • Figure 3.7 Global Early Phase Clinical Trial Services Market by Region: Revenue ($bn), 2019-2030
  • Figure 3.8 Global Early Phase Clinical Trial Services by Region: (% Share), 2019-2030
  • Figure 3.9 Late Phase Clinical Trial Services Market Forecasts: Revenue, $Bn 2019-2030
  • Figure 3.10 Global Late Phase Clinical Trial Services Market by Region: Revenue ($bn), 2019-2030
  • Figure 3.11 Global Late Phase Clinical Trial Services by Region: (% Share,) 2019-2030
  • Figure 3.12 Other Pharma Clinical Trial Services Market Forecasts: $bn 2019-2030
  • Figure 3.13 Global Other Pharma Clinical Trial Services Market by Region, 2019-2030
  • Figure 3.14 Global Other Pharma Clinical Trial Services Market Share, by Region, (% Share) 2019-2030
  • Figure 4.1 Pharma Clinical Trial Services Submarkets by End-Users: Revenue ($bn), 2019-2030
  • Figure 4.2 Clinical Trial Services Pharma Submarket: AGR (%), 2020-2030
  • Figure 4.3 Global Clinical Trial Services Pharma Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 4.4 Global Clinical Trial Services Pharma Submarket by Region: (% Share), 2019- 2030
  • Figure 4.5 Clinical Trial Services Biotech Submarket: AGR (%), 2020-2030
  • Figure 4.6 Global Clinical Trial Services Biotech Companies Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 4.7 Global Clinical Trial Services Biotech Companies Submarket by Region: (% Share), 2019-2030
  • Figure 4.8 Clinical Trial Services Other End-Users Submarket: AGR (%), 2020-2030
  • Figure 4.9 Global Clinical Trial Services Other End-Users Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 4.10 Global Clinical Trial Services Other End-Users Submarket by Region: (% Share), 2019-2030
  • Figure 5.1 Global Pharma Clinical Trial Services Market by Therapeutic Areas: (% Share), 2020
  • Figure 5.2 Global Pharma Clinical Trial Services Market by Therapeutic Areas: (% Share), 2025
  • Figure 5.3 Global Pharma Clinical Trial Services Market by Therapeutic Areas: (% Share), 2030
  • Figure 5.4 Pharma Clinical Trial Services Submarkets by Therapeutic Area: Revenue ($bn), 2019-2030
  • Figure 5.5 Cancer Clinical Trial Services Submarket: AGR (%), 2020-2030
  • Figure 5.6 Global Cancer Clinical Trial Services Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 5.7 Global Cancer Clinical Trial Services Submarket by Region: (% Share), 2019- 2030
  • Figure 5.8 Cardiovascular Diseases Clinical Trial Services Submarket: AGR (%), 2020- 2030
  • Figure 5.9 Global Cardiovascular Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 5.10 Global Cardiovascular Diseases Clinical Trial Services Submarket by Region: (% Share), 2019-2030
  • Figure 5.11 CNS Diseases Clinical Trial Services Submarket: AGR (%), 2020-2030
  • Figure 5.12 Global CNS Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 5.13 Global CNS Diseases Clinical Trial Services Submarket by Region: (% Share), 2019-2030
  • Figure 5.14 Infectious Diseases Clinical Trial Services Submarket: AGR (%), 2020-2030
  • Figure 5.15 Global Infectious Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 5.16 Global Infectious Diseases Clinical Trial Services Submarket by Region: (% Share), 2019-2030
  • Figure 5.17 Metabolic Diseases Clinical Trial Services Submarket: AGR (%), 2020-2030
  • Figure 5.18 Global Metabolic Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 5.19 Global Metabolic Diseases Clinical Trial Services Submarket by Region: (% Share), 2019-2030
  • Figure 5.20 Other Diseases Clinical Trial Services Submarket: AGR (%), 2020-2030
  • Figure 5.21 Global Other Diseases Clinical Trial Services Submarket by Region: Revenue ($bn), 2019-2030
  • Figure 5.22 Global Other Diseases Clinical Trial Services Submarket by Region: (% Share), 2019-2030
  • Figure 6.1 Regional Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.2 North American Pharma Clinical Trial Services by Country: (% Share), 2020
  • Figure 6.3 North American Pharma Clinical Trial Services by Country: (% Share), 2025
  • Figure 6.4 North American Pharma Clinical Trial Services by Country: (% Share), 2030
  • Figure 6.5 U.S. Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.6 Rest of North America Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.7 North American Pharma Clinical Trial Services by Service: Revenue ($bn), 2019-2030
  • Figure 6.8 North American Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2019-2030
  • Figure 6.9 North American Pharma Clinical Trial Services Market by End-Users: Revenue ($bn), 2019-2030
  • Figure 6.10 European Pharma Clinical Trial Services by Country (% Share), 2020
  • Figure 6.11 European Pharma Clinical Trial Services by Country (% Share), 2025
  • Figure 6.12 European Pharma Clinical Trial Services by Country (% Share), 2030
  • Figure 6.13 France Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.14 Germany Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.15 U.K. Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.16 Spain Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.17 Italy Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.18 Russia Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.19 Central and Eastern Europe (CEE) Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.20 Rest of Europe Pharma Clinical Trial Services Market: Revenue ($bn), 2019- 2030
  • Figure 6.21 European Pharma Clinical Trial Services Market by Service: Revenue ($bn), 2019-2030
  • Figure 6.22 European Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2019-2030
  • Figure 6.23 European Pharma Clinical Trial Services Market by End-users: Revenue ($bn), 2019-2030
  • Figure 6.24 Asia-Pacific Pharma Clinical Trial Services by Country: (% Share), 2020
  • Figure 6.25 Asia-Pacific Pharma Clinical Trial Services by Country: (% Share), 2025
  • Figure 6.26 Asia-Pacific Pharma Clinical Trial Services by Country: (% Share), 2030
  • Figure 6.27 China Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.28 India Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.29 Japan Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.30 South Korea Pharma Clinical Trial Services Market: Revenue ($bn), 2019- 2030
  • Figure 6.31 Rest of Asia-Pacific (APAC) Pharma Clinical Trial Services Market: Revenue ($bn), 2019-2030
  • Figure 6.32 Asia-Pacific Pharma Clinical Trial Services Market by Service: Revenue ($bn), 2019-2030
  • Figure 6.33 Asia-Pacific Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2019-2030
  • Figure 6.34 Asia-Pacific Pharma Clinical Trial Services Market by End-Users: Revenue($bn), 2019-2030
  • Figure 6.35 Rest of the World (RoW) Pharma Clinical Trial Services Market by Country (% Share), 2020
  • Figure 6.36 Rest of the World (RoW) Pharma Clinical Trial Services Market by Country (% Share), 2025
  • Figure 6.37 Rest of the World (RoW) Pharma Clinical Trial Services Market by Country (% Share), 2030
  • Figure 6.38 Latin America Pharma Clinical Trial Services Market: Revenue ($bn), 2019- 2030
  • Figure 6.39 Middle East and Africa Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.40 Brazil Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 6.41 RoW Pharma Clinical Trial Services Market by Service: Revenue ($bn), 2019- 2030
  • Figure 6.42 RoW Pharma Clinical Trial Services Market by Therapeutic Area: Revenue ($bn), 2019-2030
  • Figure 6.43 RoW Pharma Clinical Trial Services Market by End-Users: Revenue ($bn), 2019-2030
  • Figure 7.1 Market: Drivers and Restraints, 2019-2030
  • Figure 7.2 Trial Participants by Year Approved, Therapeutic Area, and Geography
  • Figure 7.3 China's Trial Initiations from 2007 to 2016
  • Figure 8.1 Quintiles IMS Holdings Inc. 2018 Annual Revenue by Business Segment: (% Share)
  • Figure 8.2 Quintiles IMS Holdings Inc. Annual Revenue 2016-2018 ($mn)
  • Figure 8.3 LabCorp (Covance Inc.) 2018 Annual Revenue by Business Segment: (% Share)
  • Figure 8.4 LabCorp Annual Revenue 2016-2018 ($bn)
  • Figure 8.5 Pharmaceutical Product Development (PPD) 2010 Annual Revenue by Business Segment: (% Share)
  • Figure 8.6 Parexel International Corporation 2017 Annual Revenue by Business Segment: (% Share)
  • Figure 8.7 Parexel International Corporation Annual Revenue 2016-2018 ($mn)
  • Figure 8.8 ICON Annual Revenue 2016-2018 ($mn)
  • Figure 8.9 INC Research 2016 Annual Revenue by Business Segment: (% Share)
  • Figure 8.10 INC Research Annual Revenue 2012-2016 ($bn)
  • Figure 8.11 PRA Health Sciences 2017 Annual Revenue by Business Segment: (% Share)
  • Figure 8.12 PRA Health Sciences Annual Revenue 2016-2018 ($mn)
  • Figure 8.13 Charles River Laboratories 2018 Annual Revenue by Business Segment: (% Share)
  • Figure 8.14 Charles River Laboratories Annual Revenue 2016-2018 ($mn)
  • Figure 8.15 Wuxi AppTec Annual Revenue 2016-2018 ($mn)
  • Figure 10.1 Global Pharma Clinical Trial Services Market: Revenue($bn), 2019-2030
  • Figure 10.2 Pharma Clinical Trial Services Market by Region: Revenue ($bn), 2019-2030

List of Companies Mentioned in the Report:

  • Almac Group
  • Ancillare, LP
  • AstraZeneca
  • Bayer
  • Catalent, Inc
  • Charles River Laboratories
  • Chiltern International Ltd
  • CNS Vital Signs
  • Covance Inc.
  • Czura Thornton
  • Forest Pharmaceuticals
  • GlaxoSmithKline (GSK)
  • ICON
  • INC Research Holdings
  • Institute for Medical Research Management and Biometrics
  • inVentiv Health
  • Jasper Clinical Research and Development Inc.
  • Java Clinical
  • JCL Bioassay Corporation (part of CMIC Holdings)
  • KLIFO
  • Korea National Enterprise for Clinical Trials
  • LabCorp (Covance Inc.)
  • Merck KGaA
  • Novartis
  • Parexel International Corporation
  • Pfizer
  • Pharmaceutical Product Development (PPD), LLC
  • PRA Health Sciences
  • Quintiles, Laboratory Corporation of America (LabCorp)
  • Roche
  • Sanofi
  • Syneos Health
  • Wuxi AppTec Inc
  • List Organizations Mentioned in the Report
  • Accreditation of Human Research Protection Programs (AAHRPP)
  • ACRP: Association of Clinical Research Professionals
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • International Conference of Harmonisation (ICH)
  • Japan Pharmaceutical Manufacturers Association (JPMA)
  • Ministry of Health, Labour and Welfare (MHLW)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Society for Clinical Trials (SCT)
  • The American Association of Clinical Endocrinologists (AACE)
  • The Association of Clinical Research Organizations (ACRO)
  • The Food and Drug Administration (FDA)
  • The Society of Clinical Research Associates, Inc. (SOCRA)
  • United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA)